SEC opens informal probe of Elan's Tysabri withdrawal

04/12/2005 | Wall Street Journal, The

Dublin-based Elan reported the U.S. SEC is conducting an informal inquiry regarding the Feb. 28 announcement that Elan and Biogen Idec were withdrawing the multiple sclerosis drug Tysabri from the market. Elan's stock price dropped following the announcement, and a company spokeswoman said the SEC "typically conducts a routine information gathering" when there is a significant change in stock prices.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY